Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of CSL Behring patents

List of CSL Behring patents

List of EBay patents

List of Cardiome Pharma patents

List of TeleSign patents

List of companies in Howard Lindzon's investment portfolio

Companies in the Version Control System industry

Patents where

Current Assignee

Name

is

CSL Behring

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 8172824 Apparatus for combining components under sterile conditions	Patent 8172824 was granted and assigned to CSL Behring on May, 2012 by the United States Patent and Trademark Office.		CSL Behring		United States Patent and Trademark Office	8172824	May 8, 2012
	‌ US Patent 11554156 Pharmaceutical formulations of C1 esterase inhibitor	Patent 11554156 was granted and assigned to CSL Behring on January, 2023 by the United States Patent and Trademark Office.	CSL Behring	CSL Behring		United States Patent and Trademark Office	11554156	January 17, 2023
	‌ US Patent 8119137 Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII	Patent 8119137 was granted and assigned to CSL Behring on February, 2012 by the United States Patent and Trademark Office.		CSL Behring		United States Patent and Trademark Office	8119137	February 21, 2012
	‌ US Patent 9320783 Methods of treatment using alpha-1-antitrypsin compositions	Patent 9320783 was granted and assigned to CSL Behring on April, 2016 by the United States Patent and Trademark Office.	CSL Behring	CSL Behring		United States Patent and Trademark Office	9320783	April 26, 2016
	‌ US Patent 8722624 Alpha-1-antitrypsin compositions and methods of use	Patent 8722624 was granted and assigned to CSL Behring on May, 2014 by the United States Patent and Trademark Office.		CSL Behring		United States Patent and Trademark Office	8722624	May 13, 2014
	‌ US Patent 11224643 Methods of treatment using alpha-1-antitrypsin compositions	Patent 11224643 was granted and assigned to CSL Behring on January, 2022 by the United States Patent and Trademark Office.	CSL Behring	CSL Behring		United States Patent and Trademark Office	11224643	January 18, 2022
	‌ US Patent 8124736 Alpha-1-antitrypsin compositions	Patent 8124736 was granted and assigned to CSL Behring on February, 2012 by the United States Patent and Trademark Office.		CSL Behring		United States Patent and Trademark Office	8124736	February 28, 2012
	‌ US Patent 7777006 Method for purification of alpha-1-antitrypsin	Patent 7777006 was granted and assigned to CSL Behring on August, 2010 by the United States Patent and Trademark Office.		CSL Behring		United States Patent and Trademark Office	7777006	August 17, 2010
	‌ US Patent 10335467 Methods of treatment using alpha-1-antitrypsin compositions	Patent 10335467 was granted and assigned to CSL Behring on July, 2019 by the United States Patent and Trademark Office.	CSL Behring	CSL Behring		United States Patent and Trademark Office	10335467	July 2, 2019
	‌ US Patent 11426680 Hydrophobic charge induction chromatographic protein depleted solution	Patent 11426680 was granted and assigned to CSL Behring on August, 2022 by the United States Patent and Trademark Office.	CSL Behring	CSL Behring		United States Patent and Trademark Office	11426680	August 30, 2022
	‌ US Patent 9950046 Methods of treatment using alpha-1-antitrypsin compositions	Patent 9950046 was granted and assigned to CSL Behring on April, 2018 by the United States Patent and Trademark Office.	CSL Behring	CSL Behring		United States Patent and Trademark Office	9950046	April 24, 2018
	‌ US Patent 11744880 Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings	Patent 11744880 was granted and assigned to CSL Behring on September, 2023 by the United States Patent and Trademark Office.	CSL Behring	CSL Behring		United States Patent and Trademark Office	11744880	September 5, 2023
	‌ US Patent 11857610 Methods for reducing risk of onset of acute graft versus host disease after hematopoietic cell transplantation	Patent 11857610 was granted and assigned to CSL Behring on January, 2024 by the United States Patent and Trademark Office.	CSL Behring	CSL Behring		United States Patent and Trademark Office	11857610	January 2, 2024

13 results

0 selected

13 results

0 selected